6,7‐Dihydroxy‐3‐phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation

Abstract

Summary 6,7‐Dihydroxy‐3‐phenylcoumarin (DHPC) was tested to determine whether it had any effect on vitamin K inhibition, by investigating the prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen level and platelet count. The anticoagulant and antithrombotic effects of DHPC were compared with those of warfarin by conducting a 4 h acute trial on thromboplastin‐induced disseminated intravascular coagulation (DIC), investigating various haemostatic and antioxidant system parameters and performing a haemogram. Of most significance was that in the 5‐d DHPC trial on healthy controls, PT, APTT, fibrinogen, platelet count remained within normal levels. In the 4‐h DIC trial, both DHPC (0·025 mg/kg, i.v.) and warfarin (0·25 mg/kg, i.v.) significantly inhibited DIC, by reducing the PT, APTT, and fibrin degradation products and increasing fibrinogen levels and platelet count. In the DIC drug groups, lipid peroxidation significantly increased only in the warfarin group and glutathione significantly increased only in the DHPC group. However leucocyte count was significantly higher in the DHPC than the warfarin group. Further investigation is required for why DHPC is effective on the parameters investigated, at doses one‐tenth of those of warfarin.

Photophysical and photochemical properties of novel metallophthalocyanines bearing 7-oxy-3-(m-methoxyphenyl)coumarin groups

“…On the other hand, 3-phenylcoumarin derivatives are potent antioxidant, antimicrobial [3], antiviral [4], antidepressant [5], anticoagulant [6], and vasorelaxant [7] compounds, along with the ability to inhibit peroxidases, lipoxygenase [8,9] and monoamine oxidase enzyme (MAO-B) [10].…”

Estudo do efeito modulatório de derivados de 3-fenilcumarina nas funções de neutrófilos estimulados por imunocomplexos e análise da relação estrutura-atividade

“…et al, WAFFO et al 2000). Recentemente, Tunali et al (2004) relataram a atividade anticoagulante da 6,7-diidroxi-3-fenilcumarina, e Marchi et al 2004relataram a atividade inibitória de derivados de 3-fenilcumarinas sobre a atividade da enzima gliceraldeído-3-fosfato desidrogenase de Trypanosoma cruzi.…”

“…Recentemente, a 6,7-diidroxi-3-fenilcumarina foi descrita como inibidora da peroxidação lipídica plasmática em ratos (TUNALI et al, 2004).…”

Estudo do efeito imunomodulador do derivado 3-fenilcumarínico 6,7-diidroxi-3-[3',4'-metilenodioxifenil]-cumarina em neutrófilos humanos estimulados e em modelo animal de inflamação induzida por zimosan

“…Os derivados 3-fenilcumarínicos possuem ampla atividade biológica, como antidepressivo (Sashidhara et al, 2011;Patil et al, 2013;Sashidhara et al, 2014), anticoagulante (Tunali et al, 2004), antioxidante (Roussaki et al, 2010), inibidora da enzima lipoxigenase (Roussaki et al, 2010), inibidora da enzima monoamina oxidase B (Matos et al, 2011;Ferino et al, 2013;Patil et al, 2013), inibidora de esteróide-sulfatases (Demkowicz et al, 2016), inibidora da agregação plaquetária (Tawata et al, 1990), antibacteriana (Nkengfack et al, 2000, inibidora da enzima gliceraldeído-3-fosfato desidrogenase de Trypanosoma cruzi (De Marchi et al, 2004), inibidora da replicação viral (Olmedo et al, 2012); inibidora da fosforilação da enzima PKC (Drabikova et al, 2013) inibidora da desgranulação de mastócitos (Santos et al, 2013) e forte atividade "scavenger" de radicais de oxigênio (Roussaki et al, 2010; Svinyarov e Bogdanov, 2014).…”